Comments
Loading...

Globus Medical Analyst Ratings

GMEDNYSE
Logo brought to you by Benzinga Data
$58.96
0.360.61%
At close: -
$59.38
0.420.71%
After Hours: May 23, 4:14 PM EDT
Consensus Rating1
Buy
Highest Price Target1
$115.00
Lowest Price Target1
$68.00
Consensus Price Target1
$88.60

Globus Medical Analyst Ratings and Price Targets | NYSE:GMED | Benzinga

Globus Medical Corp has a consensus price target of $567.61 based on the ratings of 38 analysts. The high is $1350 issued by HSBC on May 10, 2024<. The low is $100 issued by Deutsche Bank on August 5, 2024. The 3 most-recent analyst ratings were released by New Street Research, Goldman Sachs, and Deutsche Bank on August 6, 2024, August 5, 2024, and August 5, 2024, respectively. With an average price target of $118.33 between New Street Research, Goldman Sachs, and Deutsche Bank, there's an implied 0.21% upside for Globus Medical Corp from these most-recent analyst ratings.

Analyst Trends and Forecast
3
1
Feb
0
0
0
0
Mar
0
0
0
0
Apr
1
May
Buy
Hold
Sell
Strong Sell
Analyst Rating and Forecast
12345
4.0
Buy
Strong Buy
Buy
Hold
Sell
Strong Sell

Analyst Firms Making Recommendations1

Truist Securities
Piper Sandler
Barclays
Stifel
Wells Fargo

1calculated from analyst ratings

Analyst Ratings for Globus Medical

Buy NowGet Alert
05/12/2025Buy Now—Truist Securities
Richard Newitter74%
$80 → $68MaintainsHoldGet Alert
05/09/2025Buy Now—Piper Sandler
Matt O'Brien52%
$100 → $80MaintainsOverweightGet Alert
04/11/2025Buy Now—Truist Securities
Richard Newitter74%
$82 → $80MaintainsHoldGet Alert
03/18/2025Buy Now—Truist Securities
Richard Newitter74%
$90 → $82MaintainsHoldGet Alert
03/18/2025Buy Now—Needham
David Saxon56%
—ReiteratesHold → HoldGet Alert
02/24/2025Buy Now—Citizens Capital Markets
David Turkaly52%
—ReiteratesMarket Perform → Market PerformGet Alert
02/24/2025Buy Now—Barclays
Matt Miksic67%
$100 → $103MaintainsOverweightGet Alert
02/21/2025Buy Now—Stifel
Mathew Blackman62%
$92 → $94MaintainsBuyGet Alert
02/21/2025Buy Now—Wells Fargo
Vik Chopra47%
$95 → $93MaintainsOverweightGet Alert
02/21/2025Buy Now—Needham
David Saxon56%
—ReiteratesHold → HoldGet Alert
02/06/2025Buy Now—Needham
David Saxon56%
—ReiteratesHold → HoldGet Alert
01/10/2025Buy Now—Canaccord Genuity
William Plovanic60%
$92 → $101MaintainsBuyGet Alert
01/09/2025Buy Now—B of A Securities
Craig Bijou77%
$80 → $97UpgradeUnderperform → NeutralGet Alert
01/09/2025Buy Now—Needham
David Saxon56%
—ReiteratesHold → HoldGet Alert
12/18/2024Buy Now—Truist Securities
Richard Newitter74%
$85 → $90MaintainsHoldGet Alert
12/17/2024Buy Now—Roth MKM
Jason Wittes52%
$100 → $115MaintainsBuyGet Alert
12/12/2024Buy Now—BTIG
Ryan Zimmerman71%
$87 → $91MaintainsBuyGet Alert
12/11/2024Buy Now—Wells Fargo
Vik Chopra47%
$88 → $95MaintainsOverweightGet Alert
12/09/2024Buy Now—Canaccord Genuity
William Plovanic60%
$85 → $92MaintainsBuyGet Alert
12/02/2024Buy Now—Morgan Stanley
Drew Ranieri47%
$83 → $100UpgradeEqual-Weight → OverweightGet Alert
11/11/2024Buy Now—Morgan Stanley
Drew Ranieri47%
$74 → $83MaintainsEqual-WeightGet Alert
11/07/2024Buy Now—Needham
David Saxon56%
—Reiterates → HoldGet Alert
11/06/2024Buy Now—Stifel
Mathew Blackman62%
$80 → $92MaintainsBuyGet Alert
11/06/2024Buy Now—Canaccord Genuity
William Plovanic60%
$79 → $85MaintainsBuyGet Alert
11/06/2024Buy Now—Roth MKM
Jason Wittes52%
$100 → $100ReiteratesBuy → BuyGet Alert
11/06/2024Buy Now—RBC Capital
Shagun Singh58%
$80 → $92MaintainsOutperformGet Alert
11/06/2024Buy Now—Wells Fargo
Vik Chopra47%
$78 → $88MaintainsOverweightGet Alert
11/06/2024Buy Now—Piper Sandler
Matt O'Brien52%
$80 → $100MaintainsOverweightGet Alert
11/06/2024Buy Now—B of A Securities
Craig Bijou77%
$55 → $80MaintainsUnderperformGet Alert
11/06/2024Buy Now—Needham
David Saxon56%
—Reiterates → HoldGet Alert
10/14/2024Buy Now—BTIG
Ryan Zimmerman71%
$77 → $78MaintainsBuyGet Alert
10/08/2024Buy Now—RBC Capital
Shagun Singh58%
$78 → $80MaintainsOutperformGet Alert
08/28/2024Buy Now—BTIG
Ryan Zimmerman71%
$75 → $77MaintainsBuyGet Alert
08/08/2024Buy Now—Barclays
Matt Miksic67%
$85 → $93MaintainsOverweightGet Alert
08/07/2024Buy Now—RBC Capital
Shagun Singh58%
$76 → $78MaintainsOutperformGet Alert
08/07/2024Buy Now—Truist Securities
Richard Newitter74%
$78 → $79MaintainsHoldGet Alert
08/07/2024Buy Now—Wells Fargo
Vik Chopra47%
$60 → $78UpgradeEqual-Weight → OverweightGet Alert
08/07/2024Buy Now—Needham
David Saxon56%
—Reiterates → HoldGet Alert
07/16/2024Buy Now—Truist Securities
Richard Newitter74%
$63 → $78MaintainsHoldGet Alert
07/15/2024Buy Now—BTIG
Ryan Zimmerman71%
$72 → $75MaintainsBuyGet Alert
07/15/2024Buy Now—Morgan Stanley
Drew Ranieri47%
$67 → $71MaintainsEqual-WeightGet Alert
05/29/2024Buy Now—BTIG
Ryan Zimmerman71%
$63 → $72MaintainsBuyGet Alert
05/20/2024Buy Now—Piper Sandler
Matt O'Brien52%
$60 → $80UpgradeNeutral → OverweightGet Alert
05/09/2024Buy Now—Barclays
Matt Miksic67%
$83 → $85MaintainsOverweightGet Alert
05/08/2024Buy Now—BTIG
Ryan Zimmerman71%
$60 → $63MaintainsBuyGet Alert
05/08/2024Buy Now—Piper Sandler
Matt O'Brien52%
$55 → $60MaintainsNeutralGet Alert
05/08/2024Buy Now—Stifel
Mathew Blackman62%
$64 → $70MaintainsBuyGet Alert
05/08/2024Buy Now—Needham
David Saxon56%
—Reiterates → HoldGet Alert
03/18/2024Buy Now—BTIG
Ryan Zimmerman71%
→ $60UpgradeNeutral → BuyGet Alert
02/21/2024Buy Now—Canaccord Genuity
Caitlin Cronin41%
→ $79ReiteratesBuy → BuyGet Alert
02/21/2024Buy Now—Truist Securities
Richard Newitter74%
$58 → $60MaintainsHoldGet Alert
01/11/2024Buy Now—RBC Capital
Shagun Singh58%
$70 → $70ReiteratesOutperform → OutperformGet Alert
12/22/2023Buy Now—Truist Securities
Richard Newitter74%
$53 → $58MaintainsHoldGet Alert
12/20/2023Buy Now—Canaccord Genuity
Kyle Rose68%
$67 → $71MaintainsBuyGet Alert
11/14/2023Buy Now—Morgan Stanley
Drew Ranieri47%
$60 → $53MaintainsEqual-WeightGet Alert
11/08/2023Buy Now—Truist Securities
Richard Newitter74%
$58 → $53MaintainsHoldGet Alert
10/20/2023Buy Now—Roth MKM
Jason Wittes52%
→ $75Initiates → BuyGet Alert
10/12/2023Buy Now—Barclays
Matt Miksic67%
$77 → $86MaintainsOverweightGet Alert
09/19/2023Buy Now—Stifel
Mathew Blackman62%
→ $61UpgradeHold → BuyGet Alert
09/15/2023Buy Now—Wells Fargo
Vik Chopra47%
$63 → $58MaintainsEqual-WeightGet Alert
09/05/2023Buy Now—Truist Securities
Richard Newitter74%
→ $65ReiteratesHold → HoldGet Alert
08/07/2023Buy Now—Truist Securities
Richard Newitter74%
$68 → $65MaintainsHoldGet Alert
08/07/2023Buy Now—Barclays
Matt Miksic67%
$75 → $77MaintainsOverweightGet Alert
08/04/2023Buy Now—Wells Fargo
Vik Chopra47%
$61 → $63MaintainsEqual-WeightGet Alert
07/19/2023Buy Now—Truist Securities
Richard Newitter74%
$64 → $68MaintainsHoldGet Alert
05/31/2023Buy Now—Morgan Stanley
Drew Ranieri47%
$64 → $60MaintainsEqual-WeightGet Alert
05/24/2023Buy Now—JMP Securities
David Turkaly52%
—Reiterates → Market PerformGet Alert
05/05/2023Buy Now—Truist Securities
Richard Newitter74%
$66 → $64MaintainsHoldGet Alert
03/30/2023Buy Now—Canaccord Genuity
Kyle Rose68%
→ $67UpgradeHold → BuyGet Alert
03/28/2023Buy Now—Canaccord Genuity
Kyle Rose68%
→ $67Reiterates → HoldGet Alert
02/22/2023Buy Now—Morgan Stanley
Drew Ranieri47%
$78 → $64MaintainsEqual-WeightGet Alert
02/22/2023Buy Now—Canaccord Genuity
Kyle Rose68%
$75 → $67MaintainsHoldGet Alert
02/22/2023Buy Now—Wells Fargo
Vik Chopra47%
$67 → $61MaintainsEqual-WeightGet Alert
02/13/2023Buy Now—B of A Securities
Craig Bijou77%
$83 → $63DowngradeBuy → UnderperformGet Alert
02/10/2023Buy Now—Wells Fargo
Vik Chopra47%
$82 → $67DowngradeOverweight → Equal-WeightGet Alert
02/10/2023Buy Now—Truist Securities
Richard Newitter74%
→ $70DowngradeBuy → HoldGet Alert
02/10/2023Buy Now—Loop Capital
Jason Wittes52%
$90 → $70DowngradeBuy → HoldGet Alert
02/10/2023Buy Now—Needham
David Saxon56%
—DowngradeBuy → HoldGet Alert
02/10/2023Buy Now—BTIG
Ryan Zimmerman71%
—DowngradeBuy → NeutralGet Alert
02/09/2023Buy Now—Piper Sandler
Matt O'Brien52%
—DowngradeOverweight → NeutralGet Alert
01/06/2023Buy Now—Morgan Stanley
Drew Ranieri47%
$68 → $78MaintainsEqual-WeightGet Alert
12/20/2022Buy Now—Truist Securities
Richard Newitter74%
$74 → $85MaintainsBuyGet Alert
12/12/2022Buy Now—Wells Fargo
Vik Chopra47%
$74 → $82MaintainsOverweightGet Alert
11/09/2022Buy Now—Morgan Stanley
Drew Ranieri47%
$66 → $68MaintainsEqual-WeightGet Alert
10/18/2022Buy Now—Barclays
Matt Miksic67%
→ $69Initiates → OverweightGet Alert
10/12/2022Buy Now—Jefferies
Matthew Taylor70%
→ $75Initiates → BuyGet Alert
10/11/2022Buy Now—Morgan Stanley
Drew Ranieri47%
$62 → $66MaintainsEqual-WeightGet Alert
08/05/2022Buy Now—Piper Sandler
Matt O'Brien52%
$80 → $75MaintainsOverweightGet Alert
07/20/2022Buy Now—Truist Securities
Richard Newitter74%
$76 → $71MaintainsBuyGet Alert
07/15/2022Buy Now—Morgan Stanley
Drew Ranieri47%
$68 → $62MaintainsEqual-WeightGet Alert

FAQ

Q

What is the target price for Globus Medical (GMED) stock?

A

The latest price target for Globus Medical (NYSE:GMED) was reported by Truist Securities on May 12, 2025. The analyst firm set a price target for $68.00 expecting GMED to rise to within 12 months (a possible 14.52% upside). 42 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Globus Medical (GMED)?

A

The latest analyst rating for Globus Medical (NYSE:GMED) was provided by Truist Securities, and Globus Medical maintained their hold rating.

Q

When was the last upgrade for Globus Medical (GMED)?

A

The last upgrade for Globus Medical Inc happened on January 9, 2025 when B of A Securities raised their price target to $97. B of A Securities previously had an underperform for Globus Medical Inc.

Q

When was the last downgrade for Globus Medical (GMED)?

A

The last downgrade for Globus Medical Inc happened on February 13, 2023 when B of A Securities changed their price target from $83 to $63 for Globus Medical Inc.

Q

When is the next analyst rating going to be posted or updated for Globus Medical (GMED)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Globus Medical, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Globus Medical was filed on May 12, 2025 so you should expect the next rating to be made available sometime around May 12, 2026.

Q

Is the Analyst Rating Globus Medical (GMED) correct?

A

While ratings are subjective and will change, the latest Globus Medical (GMED) rating was a maintained with a price target of $80.00 to $68.00. The current price Globus Medical (GMED) is trading at is $59.38, which is out of the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

People Also Watch